Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM8O3R9)

Drug Name
APG-1252 Drug Info
Indication
Disease Entry ICD 11 Status REF
Small-cell lung cancer 2C25.Y Phase 1/2 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Cross-matching ID
PubChem CID
76900653
TTD Drug ID
DM8O3R9

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Apoptosis regulator Bcl-2 (BCL-2) TTJGNVC BCL2_HUMAN Inhibitor [3]
Apoptosis regulator Bcl-xL (BCL-xL) TTU1E82 B2CL1_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Apoptosis regulator Bcl-xL (BCL-xL) DTT BCL2L1 4.863 5.664 6.092 5.843
Apoptosis regulator Bcl-2 (BCL-2) DTT BCL2 3.963 4.739 4.146 4.878
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Small-cell lung cancer
ICD Disease Classification 2C25.Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Apoptosis regulator Bcl-2 (BCL-2) DTT BCL2 2.52E-02 0.17 0.72
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04210037) Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206.